Cargando…

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer

PURPOSE: Breast cancer (BC) is a heterogeneous disease consisting of various subtypes, with different prognostic and therapeutic outcomes. The amino acid transporter, SLC7A8, is overexpressed in oestrogen receptor-positive BC. However, the consequence of this overexpression, in terms of disease prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	El Ansari, Rokaya, Alfarsi, Lutfi, Craze, Madeleine L., Masisi, Brendah K., Ellis, Ian O., Rakha, Emad A., Green, Andrew R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182634/ https://www.ncbi.nlm.nih.gov/pubmed/32200487 http://dx.doi.org/10.1007/s10549-020-05586-6

Ejemplares similares

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2021)

Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer
por: Masisi, Brendah K., et al.
Publicado: (2021)

The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes
por: El Ansari, Rokaya, et al.
Publicado: (2018)

Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer
por: Ansari, Rokaya El, et al.
Publicado: (2019)

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours
por: El Ansari, Rokaya, et al.
Publicado: (2018)

Phenotypic characterisation of breast cancer: the role of CDC42
por: Chrysanthou, Eleni, et al.
Publicado: (2017)

Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer
por: Althobiti, Maryam, et al.
Publicado: (2021)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer
por: Morotti, Matteo, et al.
Publicado: (2020)

The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development
por: Aljohani, Abrar I., et al.
Publicado: (2022)

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
por: Aleskandarany, Mohammed, et al.
Publicado: (2015)

Connexin 43 is an independent predictor of patient outcome in breast cancer patients
por: Chasampalioti, Maria, et al.
Publicado: (2018)

Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers
por: Savva, Constantinos, et al.
Publicado: (2019)

Biological and clinical significance of PARP1 protein expression in breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy
por: Al-Subhi, Nouf, et al.
Publicado: (2018)

The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
por: Althobiti, Maryam, et al.
Publicado: (2020)

Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers
por: Ahmad, Dena A. J., et al.
Publicado: (2016)

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival
por: Joseph, Chitra, et al.
Publicado: (2020)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2020)

Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer
por: Elsharawy, Khloud A., et al.
Publicado: (2020)

The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer
por: Kariri, Yousif, et al.
Publicado: (2022)

Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
por: Muftah, Abir A., et al.
Publicado: (2017)

Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients
por: Mirza, Sameer, et al.
Publicado: (2013)

The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS)
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2020)

Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases
por: Rajput, Ashish B., et al.
Publicado: (2007)

Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2019)

Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer
por: Nitze, Louise Maymann, et al.
Publicado: (2013)

Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients
por: Zhao, Xiangshan, et al.
Publicado: (2012)

Tristetraprolin mediates the anti-proliferative effects of metformin in breast cancer cells
por: Pandiri, Indira, et al.
Publicado: (2016)

The intra-tumoural stroma in patients with breast cancer increases with age
por: Vangangelt, Kiki M. H., et al.
Publicado: (2019)

Hydroxyethylcellulose as a methotrexate carrier in anticancer therapy
por: Ciekot, Jarosław, et al.
Publicado: (2020)

Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes
por: Joseph, Chitra, et al.
Publicado: (2018)

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer
por: Green, Andrew R., et al.
Publicado: (2016)

Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes
por: Teinturier, Romain, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_djvmna48m57ns8fsmcvq9vsb6m